KORU Medical SystemsKRMD
KRMD
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
90% more capital invested
Capital invested by funds: $34.9M [Q3] → $66.1M (+$31.3M) [Q4]
19% more funds holding
Funds holding: 54 [Q3] → 64 (+10) [Q4]
9.65% more ownership
Funds ownership: 27.86% [Q3] → 37.5% (+9.65%) [Q4]
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
73% less call options, than puts
Call options by funds: $12K | Put options by funds: $45K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4.50
72%
upside
Avg. target
$5.17
98%
upside
High target
$6
130%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler Jason Bednar 36% 1-year accuracy 13 / 36 met price target | 72%upside $4.50 | Neutral Downgraded | 14 Feb 2025 |
Craig-Hallum Chase Knickerbocker 41% 1-year accuracy 11 / 27 met price target | 130%upside $6 | Buy Maintained | 17 Jan 2025 |
Lake Street Frank Takkinen 50% 1-year accuracy 11 / 22 met price target | 92%upside $5 | Buy Maintained | 14 Jan 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
KORU Medical Systems, Inc. (KRMD) Q4 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - Chief Executive Officer and President Tom Adams - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Jason Bednar - Piper Sandler Anderson Shack - B. Riley Securities Michaela Smith - Canaccord Operator Greetings.

Neutral
Business Wire
2 weeks ago
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 mi.

Neutral
Business Wire
1 month ago
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that.

Positive
Seeking Alpha
1 month ago
KORU Medical Systems Has A Long Runway
KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.

Neutral
Business Wire
1 month ago
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunogl.

Neutral
Business Wire
1 month ago
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a commercialized drug therapy. The expanded indication is intended to treat a rar.

Positive
Zacks Investment Research
2 months ago
KORU Medical Systems Inc. (KRMD) is a Great Momentum Stock: Should You Buy?
Does KORU Medical Systems Inc. (KRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Neutral
Business Wire
2 months ago
KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2024 net revenues expected to be $8.9 m.

Neutral
Business Wire
4 months ago
KORU Medical Systems to Participate in Piper Sandler's 36th Annual Healthcare Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024. KORU Medical's management is scheduled to present at Piper Sandler's 36th Annual Healthcare.

Neutral
Seeking Alpha
4 months ago
KORU Medical Systems, Inc. (KRMD) Q3 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q3 2024 Earnings Call Transcript

Charts implemented using Lightweight Charts™